RUBIN’S REFLECTIONS

Follow on Twitter @IBDMD

Message to Dr. Rubin’s Patients Related to COVID-19 Boosters

Aug 13, 2021

Dear Friends and Patients, I hope this message finds you well. Please excuse the group nature of this message, but I did want to reach out with the latest update about COVID-19, and vaccinations. If you want to skip right to the booster info, scroll down to #5 below....

Tweetorial to Provide Updates on COVID-19 for Patients with IBD

Jul 30, 2021

View Twitter Thread To watch me deliver the full lecture and view the presentation, click here. I recently gave a lecture about COVID-19 and vaccination with specific information for patients with IBD. This lecture was recorded on July 21st, before the CDC issued...

Tweetorial to Clarify the NYT Article From 15 April and Further Explain/Clarify the UK CLARITY IBD Study

Apr 18, 2021

Tweetorial to Clarify the NYT Article From 15 April and Further Explain/Clarify the UK CLARITY IBD Study David T. Rubin View Twitter Thread I've previously commented about the CLARITY IBD Study (Kennedy, et al). paper in this forum, but it bears repeating and further...

SARS Vaccine and IBD Tweetorial Summary from December 1

Dec 5, 2020

SARS Vaccine and IBD Tweetorial Summary from December 1 David T. Rubin View Twitter Thread Here are my thoughts and a few updates about SARS-CoV-2 vaccines, and also about important implications for our IBD patients. Development of multiple SARS-CoV-2 vaccines in the...

Approach to Management and Interpretation of Testing Results in Patients with IBD, with Particular Attention to Restarting Therapy

Apr 21, 2020

By David T. Rubin, MD, Professor of Medicine, University of Chicago Medicine As testing for SARS-CoV-2 is expanded and serologic antibody testing becomes available, we are faced with a number of different clinical scenarios. I have outlined the different situations...

Three waves of Illness from the COVID-19 Pandemic

Apr 1, 2020

By David T. Rubin, MD, Professor of Medicine, University of Chicago Medicine I've been thinking about what comes next, and how can we get ahead of this, and propose the following for consideration. I believe that there will be three waves of illness from the...

Trial by Data: Chronic Disease & Data

by dtrubin | May 15, 2018 | Data, In the Press, monitoring | 0 Comments

Listen to Dr. Rubin featured on a podcast by Litmus Health, Trial by Data, exploring data-driven technologies and strategies shaping the future of clinical trials. Dr. Rubin talks about the importance of optimism in patient care and his own clinical trial using...

Rectal Compliance Lower Than Normal in Ulcerative Colitis, but Recovery Is Possible

by David Rubin | October 12, 2021 | In the Press | 0 Comments

"The findings did not surprise us, but supported our hypothesis that patients with UC have reduced compliance of their rectum, even when they are in remission," Dr. Rubin told Reuters Health by email. "The exciting new finding is that those who normalized their...

Dr. David T. Rubin on “How I Treat Ulcerative Colitis”

by David Rubin | April 23, 2024 | In the Press, Presentations | 0 Comments

Dr. Rubin provides an in-depth look at the treatment of ulcerative colitis, from recent advances in therapeutic agents to setting patient expectations, positioning treatments, and monitoring for disease remission or progression. Click here for the full talk from the...

Dr. David T. Rubin Reflects on How to Avoid the Next Pandemic with WGN’s Steve Dale

by David Rubin | January 18, 2022 | In the Press | 0 Comments

Click here to listen to the full interview.

Dr. Noa Krugliak Cleveland Discusses Her Award-Winning Research on Decreasing Time to Treatment Change and Remission in IBD Patients

by David Rubin | October 25, 2023 | In the Press | 0 Comments

At this year's ACG (American College of Gastroenterology) Conference in Vancouver, British Columbia, Canada, Dr. Noa Krugliak Cleveland gave an oral presentation on her award-winning abstract "Monitoring IBD by Intestinal Ultrasound Decreases Time to Treatment Change...

David T. Rubin Accepts the 2020 Sherman Prize

by David Rubin | February 1, 2022 | In the Press | 0 Comments

Watch David T. Rubin accept the 2020 Sherman Prize, which is awarded to IBD clinicians, surgeons, researchers and/or academics with extraordinary track records of achievement, making exceptional and pioneering contributions that transform IBD care.

How Does SARS-CoV-2 Become COVID-19 and How Can We Stop It?

by dtrubin | March 26, 2020 | Coronavirus, Rubin's Reflections | 0 Comments

By David T. Rubin, MD, Professor of Medicine, University of Chicago Medicine Dear Colleagues, Here is my understanding of the different stages through which SARS-CoV-2 becomes COVID-19. I also added some thoughts on how we can prevent these stages and treat patients....

UChicago Medicine Patient First in the World to Receive Ulcerative Colitis Drug Since FDA Approval

by David Rubin | September 23, 2024 | In the Press | 0 Comments

A University of Chicago Medicine patient became the first person with ulcerative colitis in the world to receive the drug guselkumab (Tremfya) since its Sept. 11 approval by the FDA for treating moderate to severe ulcerative colitis. Tremfya has been used for many...

How to identify, manage patients with high-risk ulcerative colitis

by dtrubin | November 5, 2019 | In the Press, Presentations, UC | 0 Comments

Dr. Rubin discusses his presentation at ACG 2019 in San Antonio on identifying and managing patients with high-risk ulcerative colitis with Healio Gastroenterology. “The importance of knowing who is high risk has to do with your choices of treatment and your...

SARS Vaccine and IBD Tweetorial Summary from December 1

by David Rubin | December 5, 2020 | Coronavirus, Rubin's Reflections | 0 Comments